Core Insights - Hims & Hers Health (HIMS) stock surged nearly 6% to 57.22 after announcing a menopause care program, indicating strong market interest and potential growth [1][2] - The company's expansion into menopause care is seen as a logical extension of its existing hormone replacement therapy offerings, with expectations to surpass $1 billion in revenues by 2026 [2] Company Developments - The recent launch of a testosterone replacement therapy last month set the stage for the menopause care program announcement [1] - Hims stock is approaching a buy point at 60.55, based on MarketSurge chart analysis, indicating a potential investment opportunity [2] Market Context - Hims stock ranks No. 17 on the IBD 50 list of elite growth stocks, reflecting its strong performance in the market [2] - The telehealth industry, valued at $186 billion, is experiencing significant growth, particularly in the context of weight-loss and hormone replacement therapies, which may present further investment opportunities [4]